ALIROCUMAB ADD-ON THERAPY VERSUS CONTROL IN INDIVIDUALS WITH TYPE 2 DM AND ASCVD: ODYSSEY DM-DYSLIPIDEMIA AND DM-INSULIN

Ray, KK; Del Prato, S; Muller-Wieland, D; Cariou, B; Colhoun, HM; Henry, RR; Tinahones, FJ; Domenger, C; Letierce, A; Mandel, J; Samuel, R; Bujas-Bobanovic, M; Leiter, LA

ATHEROSCLEROSIS SUPPLEMENTS, 2018; 32 (): 152